Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Cross-over Phase 2 Study of Continuous 8-Hour Intravenous Infusions of BMS-986231 in Patients With Heart Failure and Impaired Systolic Function Given a Standard Dose of Loop Diuretic
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Nov 2023
Price :
$35
*
At a glance
- Drugs Cimlanod (Primary) ; Furosemide (Primary)
- Indications Heart failure
- Focus Pharmacodynamics
- Sponsors Bristol-Myers Squibb
- 12 Nov 2023 Primary endpoint has been met. (4-hour Urinary Output Following Intravenous Administration of 40 mg Furosemide to HFrEF Participants Receiving BMS-986231 Infusion Compared to Placebo), as per Results published in the European Journal of Heart Failure
- 12 Nov 2023 Results published in the European Journal of Heart Failure
- 29 Jan 2020 Status changed from active, no longer recruiting to completed.